Mot‐2's binding protein network allows this oncoprotein to contribute to several steps of tumor development, including sequestration and inactivation of the tumor suppressor protein p53, inhibition of pro‐apoptotic proteins, alteration of the PI3K/AKT signaling pathway, activation of EMT (epithelial–mesenchymal transition), and contribution to cancer cell stemness (Black and Rezvani, 2016; Dundas et al., 2005; Gestl and Anne Bottger, 2012; Lu et al., 2011b; Na et al., 2016; Oki et al., 2011; Rozenberg et al., 2013; Wadhwa et al., 1998, 2006). The gene discussed is HSPA9; the disease is cancer.